KR20100075908A - 약제 제조용 퓨린 유도체의 용도 - Google Patents

약제 제조용 퓨린 유도체의 용도 Download PDF

Info

Publication number
KR20100075908A
KR20100075908A KR1020107007886A KR20107007886A KR20100075908A KR 20100075908 A KR20100075908 A KR 20100075908A KR 1020107007886 A KR1020107007886 A KR 1020107007886A KR 20107007886 A KR20107007886 A KR 20107007886A KR 20100075908 A KR20100075908 A KR 20100075908A
Authority
KR
South Korea
Prior art keywords
compound
formula
compounds
salt
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107007886A
Other languages
English (en)
Korean (ko)
Inventor
라우렌트 메이제르
카리마 베타예브
헤르베 가론스
나씨마 오우마타
크리스티안 베르토우
카리네 레스테르
Original Assignee
상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크
위니벨시떼 드 렌 1
위니베르시떼 파리 데카르트
유니베스티에 드 브르타뉴 오씨덴탈레
센트레 호스피탈리에르 유니베르시테르 드 브레스트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크, 위니벨시떼 드 렌 1, 위니베르시떼 파리 데카르트, 유니베스티에 드 브르타뉴 오씨덴탈레, 센트레 호스피탈리에르 유니베르시테르 드 브레스트 filed Critical 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크
Publication of KR20100075908A publication Critical patent/KR20100075908A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107007886A 2007-09-12 2008-09-12 약제 제조용 퓨린 유도체의 용도 Ceased KR20100075908A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706390A FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
FR0706390 2007-09-12

Publications (1)

Publication Number Publication Date
KR20100075908A true KR20100075908A (ko) 2010-07-05

Family

ID=39382006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107007886A Ceased KR20100075908A (ko) 2007-09-12 2008-09-12 약제 제조용 퓨린 유도체의 용도

Country Status (13)

Country Link
US (1) US8431583B2 (enExample)
EP (1) EP2187889B1 (enExample)
JP (1) JP5485893B2 (enExample)
KR (1) KR20100075908A (enExample)
CN (1) CN101918000B (enExample)
BR (1) BRPI0816810A2 (enExample)
CA (1) CA2699590A1 (enExample)
DK (1) DK2187889T3 (enExample)
ES (1) ES2444419T3 (enExample)
FR (1) FR2920776B1 (enExample)
MX (1) MX2010002680A (enExample)
RU (1) RU2500400C2 (enExample)
WO (1) WO2009068761A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
WO2013130461A1 (en) * 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
GB0315259D0 (en) 2003-06-30 2003-08-06 Cyclacel Ltd Use
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament

Also Published As

Publication number Publication date
ES2444419T3 (es) 2014-02-25
DK2187889T3 (da) 2014-02-03
BRPI0816810A2 (pt) 2017-05-16
RU2500400C2 (ru) 2013-12-10
CA2699590A1 (fr) 2009-06-04
WO2009068761A3 (fr) 2010-01-07
RU2010108505A (ru) 2011-10-20
FR2920776A1 (fr) 2009-03-13
CN101918000B (zh) 2012-11-21
EP2187889A2 (fr) 2010-05-26
CN101918000A (zh) 2010-12-15
US20100311768A1 (en) 2010-12-09
EP2187889B1 (fr) 2013-11-06
JP2010539146A (ja) 2010-12-16
JP5485893B2 (ja) 2014-05-07
MX2010002680A (es) 2010-08-26
FR2920776B1 (fr) 2012-09-28
WO2009068761A2 (fr) 2009-06-04
US8431583B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
JP7030656B2 (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ－γキナーゼ阻害剤とを含有する薬学的組成物
RU2450000C2 (ru) N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3
CN104837825B (zh) 鲁顿酪氨酸激酶抑制剂
EP2406263B1 (fr) Derivés de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en thérapeutique
CN105682655B (zh) 抗微生物化合物
JP2000501408A (ja) 特に抗増殖性を有する新規プリン誘導体およびそれらの生物学的用途
JP2003522793A (ja) 製薬におけるパウロン誘導体の使用
JP2004516297A (ja) サイクリン依存性キナーゼ（ｃｄｋ）及びグリコーゲンシンターゼキナーゼ−３（ｇｓｋ−３）の阻害剤
JPH11322610A (ja) サイクリン依存性キナーゼ阻害剤
EP3452484B1 (en) Certain protein kinase inhibitors
WO2014170873A1 (en) Compounds with a sirtuin inhibiting activity
JP2008511602A (ja) ４−アリールアゾ−３，５−ジアミノ−ピラゾール化合物及びその使用
US10358424B2 (en) Sodium salt of uric acid transporter inhibitor and crystalline form thereof
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
KR20100075908A (ko) 약제 제조용 퓨린 유도체의 용도
JPH09323928A (ja) 神経分化誘導剤
JP2023536666A (ja) 生物学的老化の減速又は防止のためのサイクリン依存性キナーゼ（ｃｄｋ）阻害剤の使用
EP2177222B1 (en) Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
EP3854401A1 (en) Cdc7-inhibiting purine derivatives and their use for the treatment of neurological conditions
JP6966044B2 (ja) タンパク質キナーゼ阻害剤としての置換されているピロロ［２，３−ｄ］ピリダジン−４−オン及びピラゾロ［３，４−ｄ］ピリダジン−４−オン
WO2018187509A1 (en) Heterocyclic compounds as chemokine receptor modulators
KR102566028B1 (ko) 신규한 다중 단백질 키나아제 억제제
EP2325169A2 (en) Lisofylline analogues and their pharmeacuetical uses
WO2024232361A1 (en) Inhibitor of megakaryocyte differentiation and maturation
WO2010103473A1 (en) Method of treatment of polycystic diseases and chronic lymphocytic leukemia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000